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Abstract
Objectives: The study aims to explore the relationship between expressions of toll-like receptor 4 (TLR4) on peripheral blood monocytes, 
serum tumor necrosis factor-alpha (TNF-α) and matrix metalloproteinase-9 (MMP-9) in patients with acute coronary syndromes(ACS), 
and to investigate the possible mechanisms of Benazepril stabilizing atherosclerosis plaques. 
Methods: 70 patients selected were randomly divided into Benazepril treatment group (35 patients) and regular treatment group 
(35 patients). Meanwhile, Stable angina pectoris (SAP) group of 32 patients and control group of 22 patients were also set up. With 
the help of flow-cytometry, expressions of TLR4 on peripheral blood monocytes of the four groups were analyzed and compared to 
show differences, correlations and changes of the above mentioned indicators. The concentration of TNF-α and MMP-9 in serum were 
  measured by enzyme linked immunosorbent assay (ELISA). 
Results: (1) Expressions of TLR4, levels of TNF-α and MMP-9 were increased and the rate was rising from the control group, to 
SAP group and then to ACS group. All these indicators in ACS group are significantly higher than those in other groups (P , 0.05). 
(ACS versus SAP, control; all (P , 0.05). (2) Multi-linear regression analysis indicates that there was a positive correlation between 
the expression level of TLR4 and serum levels of TNF-α and MMP-9 in patients with ACS (P , 0.01). (3) There is no significant 
  differences between the expression level of TLR4 and serum levels of TNF-α and MMP-9 in Benazepril treatment group and regular 
treatment group before treatment (P . 0.05) while they all fell after treatment (P , 0.05). In addition, all the indicators decreased more 
greatly than the regular treatment group. 
Conclusions: TLR4 on peripheral blood monocytes and serum TNF-α and MMP-9 in patients with coronary arteriosclerosis disease 
may be effective markers of the vulnerable plaque. Benazepril can inhibit over-expression of TLR4 and reduce serum levels of TNF-α 
and MMP-9, thus stabilize the vulnerable plaques and improve the condition of the patients with ACS.
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Acute  coronary  syndromes  (ACS)  is  often  related 
with  vulnerable  atherosclerosis  plaque  rupture,  the 
formation of thrombus and subsequent influence in 
blood flow of coronary arteries. Early diagnosis and 
treatment of vulnerable plaques exert a very important 
part in the prevention and reduction of further rupture 
and reduction of clinical emergent accidents. Recent 
studies have shown that the formation and develop-
ment of atherosclerosis are at least partly transmit-
ted through toll-like receptor 4 (TLR4)/nuclear factor 
κB (NF-κB) pathway. TLR4 cell signal transmission 
finally activate NF-κB, induce monocytes/macrophage 
to produce immunity inflammation cytokines (such 
as TNF-α), and adhesion molecules, which lead to 
plaque rupture. Current medicine research in treating 
vulnerable atherosclerosis plaque focuses mainly on 
statins. It is not clear whether angiotensin   converting 
enzyme inhibitors (ACEI) can stabilize plaques by 
inhibiting signal transduction pathways of inflamma-
tory cells toll-like receptor 4(TLR4). Based on the 
observation of expression of TLR4 on the peripheral 
blood  monocytes,  serum TNF-α  and  MMP-9,  this 
experiment aims to obtain reliable serum inflamma-
tory indicators, which indicate unstable atherosclero-
sis plaque. This article will explore the possibilities of 
treating ACS with ACEI by showing effects of such 
medicine treatment on inflammatory indicators.
Methods
Objects
(1) We selected 70 ACS patients (42 UAP and 28 AMI), 
including 41 males and 29 females. We divided them 
into two groups, respectively regular treatment group 
and Benazepril treatment group. The 35 members of 
the regular treatment group consists of 21 males and 
14 females with an average age of 58.9 ± 12.1, while 
the Benazepril treatment group involves 22 males and 
13 females with and average age of 61.2 ± 13.1. The 
regular treatment group use similar medical manage-
ment (such as nitric acid ester, aspirin, beta-blocker, 
statin  and  low  molecule  heparin).  The  Benazepril 
treatment group use Benazepril apart from these reg-
ular medicines. (2) 32 stable angina pectoris (SAP) 
patients of 22 males and 10 females have an aver-
age age of 56.8 ± 13.6. The diagnosis of UAP, AMI 
and SAP conforms to the standard set by guideline of 
American College of Cardiology/The American Heart 
Association (ACC/AHA) with a further confirmation 
of coronary angiography. Exclusion criteria included 
acute infection, malignancy, autoimmunity diseases, 
vascular diseases, severe liver or kidney diseases or 
operations and injuries within one week. (3) Control 
group comprises patients without a history of high 
blood pressure, diabetes or coronary heart disease. 
After checking with electrocardiogram (ECG), myo-
cardium enzymology and coronary coronary arteriog-
raphy, these 22 patients of 15 males and 7 females do 
not have coronary heart disease.
Blood sampling and laboratory 
determinations
Blood  was  drawn  in  the  sitting  position  from  the 
antecubital  vein  respectively  at  the  day  of  admis-
sion and 4 weeks after treatment between 8:00 and 
9:00 Am in the fasting state. All medications were 
withdrawn for at least 12 h. The blood samples were 
immediately cooled on ice.1 ml of the blood is anti-
coagulated by potassium ethylene diamine tetraacetic 
acid (EDTA-K2), Serum was obtained by subsequent 
centrifugation at 3000 g for 10 min. All samples were 
stored at −75 °C until assayed.
(1)  Flow  cytometer  (FCM)  is  used  to  measure 
expressions of TLR4 on the peripheral blood mono-
cytes. 100 ul whole blood anti-coagulate with EDTA-K2 
was obtained, added 20 ul hTLR4 antibody (mouse anti-
human monoclonal antibody, clone HTA125, IgG2a, 
Biolegend, San Diego, America) conjugated with PE to 
it and mixed them, Cells were incubated with hTLR4 
antibody for 30 minutes under room temperature, then 
fixed it up and broken the membrane, After cells were 
washed with staining buffer (PBS containing 0.1% BSA 
and 0.1% sodium azide), and with sham control, analy-
sis  by  Flow  cytometry.  (Coulter  Company,  McLean 
America). (2) TNF-α and MMP-9 were determined by 
commercially available enzyme-linked immunosorbent 
assay (TPI company, Houston, Texas Area, America).
Statistics
The Statistical Package for the Social Science (SPSS 
for windows 12.0) was employed for statistical analy-
sis. Continuous variables are expressed as mean ± SD 
(x − ± S). The differences between groups adopted a 
repeated measures ANOVA while the correlation was 
analyzed with multiple linear regression analysis. Sta-
tistical significant was defined at a P value of ,0.05.
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Variable Acs  
group (n = 70)
Benazepril  
group (n = 40)
Regular treatment  
group (n = 30)
sAp  
group (n = 32)
control  
group (n = 22)
Age (yrs) 59.9 ± 11.9 61.2 ± 13.1 58.9 ± 12.1 56.8 ± 13.6 58.6 ± 8.3
Male/female ratio 41/29 21/14 22/13 22/10 15/7
BMI (kg/m2) 23.9 ± 2.6 24.1 ± 2.7 23.5 ± 2.6 25.3 ± 1.9 24.0 ± 2.7
Smokers 24 14 10 7 11
Hypertension 30 17 13 10 0
history of DM 14 6 5 4 1
LDL-C (mmol/L) 2.0 ± 0.6 2.1 ± 0.5 2.2 ± 0.4 1.9 ± 0.5 1.8 ± 0.4
Abbreviations: BMI, body mass index; ACS, acute coronary syndromes; SAP, stable angina pectoris; DM, diabetes mellitus; LDL-C, low density lipoprotein 
cholesterol.
Results
Subject profile
Table 1 present the clinical characteristics of the 
  subjects  investigated.  The  differences  between 
ACS, SAP and control subjects in gender, age, Body 
Mass Index (BMI), percentage of smokers, DM and 
the level of LDL-C were not significant (P . 0.05).
There is no significant differences in gender, age, 
BMI,   percentage of smokers, high blood pressure, 
DM  and  the  level  of  LDL-C  between  regular 
treatment  group  and  Benazepril  treatment  group 
(P . 0.05).
The changes of expressions of TLR4 on peripheral 
blood monocytes, TNF-α and MMP-9 in ACS, SAP 
and control groups. As shown in Table 2, expressions 
of  TLR4  and  levels  of  TNF-α  and  MMP-9  were 
significantly  increased  in ACS  group  (P  ,  0.05) 
(Table 2).
The correlation between TLR4 and TnF-α, 
MMP-9 in ACS patients
Multiple  linear  regression  analysis  showed  that 
there was a positive correlation between the expres-
sion level of TLR4 and serum levels of TNF-α and 
MMP-9 in patients with ACS (P , 0.01).
Comparison  of  the  expression  level  of  TLR4 
and serum levels of TNF-α and MMP-9 before and 
after  treatment.  There  is  no  significant  difference 
between  the  expression  level  of  TLR4  and  serum 
levels of TNF-α and MMP-9 in Benazepril treatment 
group and regular treatment group before treatment 
(P . 0.05).While these indicators all fell after treat-
ment (P , 0.05). In addition, all of them decreased 
more greatly in Benazepril treatment group than in 
the regular treatment group. (Table 3).
Discussion
Recent studies have shown that the formation and 
development  of  atherosclerosis  are  at  least  partly 
transmitted through toll-like receptor 4(TLR4)/nuclear 
factor κB (NF-κB) pathway. TLR4 cell signal trans-
mission finally activate NF-κB, induce monocytes/
macrophage  to  produce  immunity  inflammation 
cytokines (such as TNF-α), and adhesion molecules, 
which lead to coronary heart disease.1,2 Methe reported 
that the increase of expressions of TLR4 on periph-
eral blood monocytes in patients with ACS had cor-
relation with the stability of plaques.3 The results of 
study by Ishikawa indicated expression of both sys-
temic and local plaque TLR4 may be one of the mech-
anisms  responsible  for  the  pathogenesis  of  AMI.4 
Pro-inflammatory cytokine plays an important part 
in the pathology process of the ACS. Inflammatory 
cytokine can activate the secretion of matrix metal-
loproteinases (MMPs) and lead to the instability and 
vulnerability of plaques. Cytokine is a multifunctional 
medium of inflammation and immunoreaction, which 
was secreted and released by local inflammation cells. 
Its autocrine and paracrine affect the function of vas-
cular wall cells. Studies showed that vascular smooth 
muscle cell stimulated by IL-1 and TNF-α not only 
increased the synthetic secretion of MMP-1, but also 
activated MMP-2 and MMP-9 in the form of zymo-
gen and started to synthesize and secrete MMP-3.1,5 
Although the activity of MMPs is inhibited by its 
tissue inhibitors of metalloproteinase (TIMP), nor-
mally vascular smooth muscle cells will secrete a tiny 
amount of TIMP-1 and TIMP-2 for modulation and 
cytokine which does nothing to its secretion. The net 
result is that MMPs has advantage over the degrada-
tion of extracellular matrix (ECM), the intensity of 
Toll-like receptor 4 and ACS
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This study shows that the expression level of TLR4, 
serum levels of TNF-α and MMP-9 indicate a rising 
tendency from control group to SAP group and then 
to ACS group. All these indicators in the last group 
(ACS) is significantly higher than those in the first 
two (P , 0.05). It is also found out that the expres-
sion level of TLR4 has a positive correlation with 
serum levels of TNF-α and MMP-9, which affirms 
the correlation between them from serology. The rise 
of TLR4, TNF-α and MMP-9 is closely related to 
ACS, which may be applied as a serology indicator 
in treatment of patients with coronary heart disease. 
However, the sample in this study is limited and it 
needs further experiment to prove.
Angiotensin II (ang. II) can affect various vascular 
  system factors which lead to the instability of plaques. 
It causes malfunction of endothelium and arterioscle-
rosis plaques. It also induces expressions of vascular 
cell adhesion molecular 1 and contributes to the attach-
ment of monocyte to endothelial cell and produces 
oxygen-derived free radicals. All these will bring about 
pre-inflammatory  state  and  instability  of  plaques.6 
ACE inhibitors or angiotensin II receptor antagonists 
are  useful  in  changing  it.  The  subsection  analysis 
SECURE  of  HOPE  study  indicates  that  Ramipril 
of 10 mg can greatly lower the thickness of carotid 
endarterium. TREND study show that Quinapril can 
bring down the contraction reaction of blood vessel 
to the inducement of acetylcholine. Our past clinical 
research also proved that ACEI preparation Fosinopril 
can inhibit NF-κB signal path, inflammatory cytokine 
TNF-α and MMPs/TIMPs.7 The results of this study 
show that ACEI preparation Benazepril can remark-
ably reduce TLR4, TNF-α and MMP-9. It is estimated 
that ACEI can stabilize vulnerable plaques of athero-
sclerosis and reduce the number of acute cardiovascu-
lar events by inhibiting the over-expression of TLR4 
and reduce serum levels of TNF-α and MMP-9.
conclusions
TLR4  on  peripheral  blood  monocytes  and  serum 
TNF-α  and  MMP-9  in  patients  with  coronary 
  arteriosclerosis disease may be effective markers of 
the vulnerable plaque. Benazepril can inhibit over-
  expression of TLR4 and reduce serum levels of TNF-α 
and MMP-9, thus stabilize the vulnerable plaques and 
improve the condition of the patients with ACS.
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Table 2. Comparison of TLR4 on peripheral blood monocytes, TnF-α and MMP-9 between patients with ACS, SAP and 
control subjects. (− x ± s).
  TLR4 (%) TnF-α (pg/ml) MMp-9 (ng/L)
ACS group (n = 70)    80.3 ± 11.45*▲ 17.53 ± 6.62*▲ 14.25 ± 5.63*▲
SAP group (n = 22) 60.35 ± 15.5 10.26 ± 2.83    2.31 ± 1.91
Control group (n = 32)    51.3 ± 10.92    9.15 ± 2.30    1.86 ± 0.97
notes: *P , 0.01,vs. control group; ▲P , 0.01 vs. SAP group.
Abbreviations: TLR4, toll-like receptor 4; TnF-α, tumor necrosis factor-alpha; MMP-9, matrix metalloproteinase-9; ACS, acute coronary syndromes; 
SAP, stable angina pectoris.
Table  3.  Comparisons  of  the  expression  level  of  TLR4  and  serum  levels  of  TnF-α  and  MMP-9  before  and  after   
treatment. (− x ± s).
  TLR4 (%) TnF-α (pg/ml) MMp-9 (ng/L)
Before  After treatment Before  After treatment Before  After treatment
Regular  
group (n = 40)
79.63 ± 10.87  61.25 ± 9.66* 16.79 ± 6.13  12.75 ± 5.98* 14.16 ± 5.36   3.97 ± 1.11*
Benazepril  
group (n = 30)
81.22 ± 11.91  52.29 ± 8.47*, 18.02 ± 6.71  9.86 ± 5.04*, 14.35 ± 5.97  2.13 ± 1.01*,
notes: *P , 0.05 vs. before treatment group; P , 0.05 vs. regular treatment group. See Table 2 for abbreviations.
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